Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease.
Published
Journal Article
Leucine-rich repeat kinase-2 (LRRK2) mutations are a common cause of Parkinson's disease. Here we identify inhibitors of LRRK2 kinase that are protective in in vitro and in vivo models of LRRK2-induced neurodegeneration. These results establish that LRRK2-induced degeneration of neurons in vivo is kinase dependent and that LRRK2 kinase inhibition provides a potential new neuroprotective paradigm for the treatment of Parkinson's disease.
Full Text
Duke Authors
Cited Authors
- Lee, BD; Shin, J-H; VanKampen, J; Petrucelli, L; West, AB; Ko, HS; Lee, Y-I; Maguire-Zeiss, KA; Bowers, WJ; Federoff, HJ; Dawson, VL; Dawson, TM
Published Date
- September 2010
Published In
Volume / Issue
- 16 / 9
Start / End Page
- 998 - 1000
PubMed ID
- 20729864
Pubmed Central ID
- 20729864
Electronic International Standard Serial Number (EISSN)
- 1546-170X
Digital Object Identifier (DOI)
- 10.1038/nm.2199
Language
- eng
Conference Location
- United States